Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Neprilysin


Brief Information

Target Synonym:EC:,EC 3.4.24,Atriopeptidase,NEP,SFE,Membrane Metallo-Endopeptidase (Neutral Endopeptidase, Enkephalinase, CALLA, CD10),Membrane Metallo-Endopeptidase Variant 1,Membrane Metallo-Endopeptidase Variant 2,Neprilysin-390,Neprilysin-411,CD10 Antigen,EC,CMT2T,SCA43,EPN,MME,Enkephalinase,CALLA,Neutral endopeptidase,Common acute lymphocytic leukemia antigen,Neprilysin,CD10,Membrane Metalloendopeptidase,Neutral Endopeptidase 24.11,Skin fibroblast elastase
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
MME-H521b Human Human Neprilysin / MME / CD10 Protein, Tag Free (active enzyme)
MME-H526a Human Human Neprilysin / MME / CD10 Protein, Fc Tag
ACRO Quality

Synonym Name



Cluster of differentiation 10 (CD10) is also known as membrane metallo-endopeptidase, neutral endopeptidase (NEP), Neprilysin, and common acute lymphoblastic leukemia antigen (CALLA), is a 90-110-kDa type II transmembrane glycoprotein normally expressed by a variety of tissues, including epithelial cells of the prostate, kidney, intestine, endometrium, adrenal glands, and lung. This zinc-dependent metalloprotease enzyme cleaves peptide bonds on the amino side of hydrophobic residues and inactivates a variety of physiologically active secreted peptides. CD20 is thought to be the rate-limiting degrading enzyme of amyloid ¦Â peptide (A¦Â) whose abnormal misfolding and aggregation in neural tissue has been implicated in the development of Alzheimer's disease (AD). CD10 is also identified as the common acute lymphoblastic leukemia antigen (CALLA) present on leukemic cells of pre-B phenotype, and thus serves as the most important biomarker in the diagnosis of human acute lymphocytic leukemia (ALL).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Sacubitril/Valsartan Sodium Hydrate LCZ-696; LCZ-696A Approved Novartis Pharma Ag Entresto, 诺欣妥, 科畅欣, Neparvis, ENTRESTO SPRINKLE, Enresuto, Enrest United States Heart Failure Novartis Pharmaceuticals Corp 2015-07-07 Breast Neoplasms; Heart Failure, Systolic; Peripheral Arterial Disease; Ventricular Dysfunction, Left; Lymphoma; Obesity; Cardiovascular Diseases; Hepatic Insufficiency; Essential Hypertension; Erectile Dysfunction; Hypertension; Coronavirus Disease 2019 (COVID-19); Postmyocardial Infarction Syndrome; Heart Diseases; Cardiomyopathy, Hypertrophic; Myocardial Infarction; Renal Insufficiency; Heart Failure Details
Racecadotril Tiorfan; Hidrasec Approved Bioprojet Pharma France Diarrhea Bioprojet Pharma 1993-03-23 Diarrhea, Infantile; Diarrhea Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Dexecadotril Phase 3 Clinical Bioprojet Pharma Gastrointestinal Diseases Details
Debio-0827 PL-37; Debio-0827 Phase 2 Clinical Pharmaleads Pain Details
STR-324 STR-324 Phase 2 Clinical Shanghai Pasteur Institute Of Chinese Academy Of Sciences Acute Pain Details
Sacubitril AHU-377 Phase 2 Clinical Novartis Pharma Ag Heart Failure; Cardiomyopathy, Hypertrophic; Insulin Resistance; Hypertension; Metabolic Diseases; Essential Hypertension; Cardiovascular Diseases; Diabetes Mellitus Details
QR-12000 QR-12000 Phase 2 Clinical Wuhan Createrna Science and Technology Co Ltd Hypertension; Essential Hypertension Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message